


## Boc-Hyp-OH

Cat. No.:	HY-I0781
CAS No.:	13726-69-7
Molecular Formula:	C <sub>10</sub> H <sub>17</sub> NO <sub>5</sub>
Molecular Weight:	231.25
Target:	ADC Linker; PROTAC Linkers
Pathway:	Antibody-drug Conjugate/ADC Related; PROTAC
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    6 months -20°C    1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (432.43 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		4.3243 mL	21.6216 mL	43.2432 mL
	5 mM		0.8649 mL	4.3243 mL	8.6486 mL
	10 mM		0.4324 mL	2.1622 mL	4.3243 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (10.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (10.81 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (10.81 mM); Clear solution

### BIOLOGICAL ACTIVITY

Description	Boc-Hyp-OH is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-Hyp-OH is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2]
IC <sub>50</sub> & Target	Non-cleavable Linker
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> .

---

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[2]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

- [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.
- [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA